EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of indapamide sustained-released on antihypertensive effect assessed by ambulatory blood pressure monitoring



Evaluation of indapamide sustained-released on antihypertensive effect assessed by ambulatory blood pressure monitoring



Zhonghua Xinxueguanbing Zazhi 30(7): 393-396, July



Objective To evaluate antihypertensive effect and safety of a new low doses 1.5 mg sustained-released formulations of indapamide (SRID). Methods 108 outpatients with mild to moderate hypertension (male 59, female 49, mean age (51 +- 11) years old) were follow-up in three hospitals. In order to evaluate the long term antihypertensive effect of SRID, 30h blood pressure monitoring before and 8 weeks after administration of SRID began at 8:00 in the morning. Trough/Peak (T/P) ratios and the average blood pressure in every hour were calculated. Meanwhile, clinic blood pressure was measured in 2, 4, 8 weeks and the main safety criterion included the serum potassium and uric acid. Results (1) The total effective rate evaluated by clinic blood pressure measurement was 67.6%. (2) Similar results of T/P ratios were calculated from group and individual data in all patients and responding patients respectively, ie, T/P of systolic blood pressure (SBP) 0.80-0.75, T/P of diastolic blood pressure (DBP) 0.79-0.74. (3) Comparing the average value of 25-30 h blood pressure with placebo control, significantly decrease was found ((142 +- 12)/(92 +- 7) mm Hg, (134 +- 12)/(89 +- 9) mm Hg, P < 0.01). (4) The peak efficacy was found in 8-19 h (93%), especially in 14-17h period after medication. (5) The main safety criterion: serum potassium showed less than 3.4 mmol/L in 8 patients, only one less than 3.0 mmol/L (2.94 mmol/L). Serum uric acid showed slight increase in 18 cases (16.7%). Conclusion SRID 1.5 mg provided effective 24h blood pressure control assessed by ambulatory blood pressure monitoring. In case of occasional delay of drug in-take, it is still effective to significantly reduce blood pressure during a missed-dose period between 25-30 h. The peak efficacy can be lasted to 14-17 h after administration of SRID. It seems to contribute to the regression of left ventricular hypertrophy.

(PDF emailed within 1 workday: $29.90)

Accession: 010616360

Download citation: RISBibTeXText



Related references

Evaluation of trough/peak ratio of indapamide 1.5 mg sustained-release form assessed by ambulatory blood pressure monitoring. Archives des Maladies du Coeur et des Vaisseaux 89 Spec No 4: 27-38, 1996

Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Medical Science Monitor 16(5): Cr266-Cr271, 2010

Evaluation of the antihypertensive efficacy and safety of using sustained release verapamil in elderly subjects using ambulatory blood pressure monitoring. Przeglad Lekarski 53(2): 73-77, 1996

Comparative evaluation of the antihypertensive efficacy of once-daily sustained-release isradipine and lacidipine using 24-hour ambulatory blood-pressure monitoring. Journal of International Medical Research 23(4): 234-243, 1995

Evaluation of antihypertensive therapy by ambulatory blood pressure monitoring and establishment of the level of antihypertensive goal on the circadian rhythm of blood pressure. Kokyu to Junkan. Respiration & Circulation 38(1): 71-76, 1990

Evaluation of daily blood pressure variability and its smoothing Antihypertensive effect of nisoldipine on ambulatory blood pressure under 24-hour noninvasive monitoring. Respiration & Circulation 42(12): 1197-1203, 1994

Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring. American Journal of Cardiology 61(5): 27c-33c, 1988

Efficacy of Antihypertensive Monotherapies Assessed by Ambulatory Blood Pressure Monitoring: Is There Really a Winner?. Journal of Clinical Hypertension 17(11): 866-867, 2016

Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring. Clinical and Experimental Hypertension. Part A, Theory and Practice 7(2-3): 395-399, 1985

Evaluation of antihypertensive effect of lacidipine with ambulatory blood pressure monitoring in 60 patients. Zhongguo Xinyao yu Linchuang Zazhi 23(1): 58-61, January, 2004

Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring. American Journal of Cardiology 70(12): 60D-66D, 1992

The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Clinical & Experimental Hypertension 21(8): 1373-1396, 1999

Antihypertensive efficacy of diltiazem SR assessed by continuous ambulatory intra-arterial blood pressure monitoring. Cardiovascular Drugs & Therapy 7(SUPPL 2): 417, 1993

Evaluation of the antihypertensive effect of delayed-action nicardipine with 24-hour ambulatory blood pressure monitoring. Therapie 43(2): 97-100, 1988

Time-effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: An ambulatory blood pressure monitoring study with Trandolapril vs. Quinapril. Fundamental & Clinical Pharmacology 16(6): 545-554, December, 2002